U.S. License Holder:
Chiesi Farmaceutici S.p.A.
Date of License:
May-09-2023
Last Update:
Dec-15-2024
FDA-Approved Indications
ELFABRIO (pegunigalsidase alfa-iwx) is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adults with confirmed Fabry disease.